Silo Pharma Inc.’s Post

𝐑𝐨𝐢𝐯𝐚𝐧𝐭 𝐚𝐧𝐝 𝐏𝐫𝐢𝐨𝐯𝐚𝐧𝐭 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐏𝐡𝐚𝐬𝐞 𝟐 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐁𝐫𝐞𝐩𝐨𝐜𝐢𝐭𝐢𝐧𝐢𝐛 𝐢𝐧 𝐍𝐨𝐧-𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐮𝐬 𝐔𝐯𝐞𝐢𝐭𝐢𝐬 Roivant (Nasdaq: ROIV) Roivant Sciences and Priovant Therapeutics Priovant Therapeutics announced positive Phase 2 results from the NEPTUNE study evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), demonstrating the strongest efficacy data observed to date. Additionally, Roivant's board authorized a share repurchase program and announced the repurchase of all shares held by Sumitomo Pharma. Matt Gline Matthew Gline, CEO of Roivant, emphasized the significance of the NIU data, highlighting Roivant's commitment to developing effective medicines in underserved indications. Jane Chung, President and COO at Priovant, expressed excitement about the potential of brepocitinib and its differentiated profile in NIU. The NEPTUNE study enrolled 26 subjects with active NIU, showing positive results for brepocitinib across multiple efficacy endpoints at week 24. Safety and tolerability were consistent with prior studies, with no new safety signals identified. Quan Dong Nguyen Quan Dong Nguyen, NEPTUNE investigator, emphasized the need for novel therapies in NIU, underscoring brepocitinib's potential as a transformative once-daily oral therapy. Ben Zimmer Benjamin Zimmer, CEO of Priovant, highlighted the study's design and the potential of brepocitinib in NIU, signaling confidence for Phase 3 trials. Priovant intends to initiate a Phase 3 program in NIU in the second half of 2024, while the ongoing Phase 3 study in dermatomyositis is expected to be fully enrolled in the third quarter of 2024. #Brepocitinib #NEPTUNEStudy #NIU #Uveitis #ClinicalTrials #MedicalResearch #Healthcare #Ophthalmology #Pharmaceuticals #ShareRepurchase #Biotech

Entera's EB613 has demonstrated the ability to increase P1NP (biomarker for bone formation) and simultaneous decrease sCTX (biomarker of bone resorption). This unique characteristic differs from commonly used anti-resorptive drugs and subcutaneous injectable PTH(1-34), Forteo® for osteoporosis. Amgen's Prolia (denosumab), an anti-resorptive, has demonstrated decreases in both CTX and P1NP. While anabolic treatment Forteo (teriparatide) has shown an increase in both P1NP and CTX. See figures on the right, below. Entera's (ENTX) oral formulation is increasing bone formation biomarker P1NP while also having a mild antiresorptive property, which is compelling and differentiated as a dual-mechanism. The other dual-mechanism drug, Amgen's Evenity®has demonstrated both a anabolic and anti-resorptive effect using a differentiated mode of action. It is a anti-sclerostin monoclonal antibody with robust anti-fracture data though it requires 2 injections every month. In contrast, Entera's dual mechanism candidate is being developed as an oral. #themoreyouknow #osteoporosis #stayinformed

𝐀𝐠𝐞-𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 (𝐀𝐌𝐃) 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐃𝐞𝐦𝐨 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐄𝐱𝐜𝐞𝐥 𝐏𝐢𝐯𝐨𝐭 𝐚𝐧𝐝 𝐓𝐨𝐂: https://lnkd.in/dC5uARq8 🔷 Age-related macular degeneration is a degenerative eye disease commonly occurring after the age of 50, leading to vision loss in the inner area of the visual field. There are two types: dry AMD - degeneration of vision due to gradual thinning of the macula; wet AMD - rapid degeneration through unhealthy growth under the retina. Treatment for AMD is primarily aimed at the wet form with anti-vascular endothelial growth factor (anti-VEGF) therapies, including Eylea (aflibercept), Lucentis (ranibizumab), and new Vabysmo (faricimab). 🔷 In 2023, the FDA authorized Syfovre, the inaugural medicine for treating dry age-related macular degeneration (AMD). Syfovre is the first treatment to receive FDA approval, having shown a reduction of around 20% in the progression of blind spots associated with advanced dry macular degeneration over a two-year period. ▪ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐀𝐠𝐞-𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 (𝐀𝐌𝐃) 𝐃𝐫𝐮𝐠𝐬  ▪ Regeneron ▪ Bayer ▪ Roche ▪ Novartis ▪ Apellis Pharmaceuticals. ▪ Coherus BioSciences. ▪ Astellas Pharma. ▪ Biogen ▪ STADA Group ▪ Formycon AG ▪ Outlook Therapeutics, Inc. ▪ Intas Pharmaceuticals. ▪ Teva Pharmaceuticals. ▪ Chengdu Kanghong Pharmaceutical Group Co.,Ltd. ▪ Sandoz ▪ Stealth BioTherapeutics ▪ Ocular Therapeutix, Inc. ▪ Opthea, ▪ Kodiak Sciences. ▪ Innovent Biologics. ▪ Bio-Thera Solutions. ▪ Alvotech ▪ ALTEOGEN Inc. ▪ Amgen. ▪ OcuMension ▪ Adverum Biotechnologies. #AgeRelatedMacularDegeneration #AMDDrugs #MacularDegenerationTreatment #WetAMD #DryAMD #AntiVEGF #VisionLoss #EyeHealth #Syfovre #Eylea #Lucentis #Vabysmo #FDAApproval #Ophthalmology

📄 Our first clinical paper on our lead product 💊 BK001 (Chitin-Glucan + simethicone) on its efficacy in IBS-patients is just published in the World Journal of Gastrointestinal Pharmacology and Therapeutics.   ✅ It is generally accepted that rapid action, safety, and tolerability are essential for the development of new IBS therapeutic strategies. 👨⚕️Well, the present study showed that BK001 [=GASTRAP® DIRECT] is safe and well tolerated. The study showed a significant and rapid improvement of all quantitative and subjective clinical endpoints (abdominal pain, bloating, flatulence, constipation, diarrhea, and dyschezia) after 2 weeks of BK001 administration. 📚 For the full details of our study: https://lnkd.in/eNDSf--C 👉 Reach out to us (info@biokuris.com) should you be interested to commercialize/distribute this product in your regions.   #chitinglucan #simethicone #gastrointestinal #IBS #BiOkuris

• Roche launches monoclonal antibody for two critical eye diseases in India ✔️ Roche Pharma India on Tuesday launched Vabysmo (faricimab) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) in India. With this product, the pharma major has forayed into the Ophthalmology space. Neovascular AMD and DME are two leading causes of vision loss worldwide. ✔️ According to the company, Vabysmo is the first and only dual-pathway-inhibitor that uniquely targets and inhibits two disease pathways linked to a number of vision threatening retinal conditions. ✔️ It neutralises both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) which are key proteins involved in the development and progression of retinal conditions, contributing to vision loss by destabilising blood vessels in the eye. As the world’s first bispecific monoclonal antibody, Vabysmo is a single molecule designed to target and inhibit the effects of two targets, providing the benefits of two medicines in one,” the company said in a statement. #pharmacovigilance #pharmaceutical #qiviflow #pharmaceuticalcompanies #pharmaceuticalindustry #iqvia #novartis #zydus #astrazeneca #novonordisk #roche #pfizer #cipla #sunpharma #alkem #intas #torrent #mankindpharma #gsk #Glenmark #elililly #abbott #suven #alembic #sanofi #drugdiscovery #aurobindo #drreddys #johnsonandjohnson #ipca #lupin #biocon #syngene

🎉 New Study Published! 🎉 Exciting news for #IBS sufferers! Our latest research, published in the World Journal of Gastrointestinal Pharmacology and Therapeutics, reveals rapid improvement in all key symptoms: abdominal pain, bloating, flatulence, constipation, diarrhea, and dyschezia. 👇 Read more

Congratulations to Keymed Biosciences Inc.! The company announced the National Medical Products Administration of China has recently approved the new drug application for stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Kangyueda (康悦达), for the indication of moderate-to-severe atopic dermatitis in adults. The marketing approval of stapokibart is based on a multi-center, randomized, double-blind, placebo-controlled Phase III study, with the co-primary endpoints being the achievement of at least a 75% improvement in Eczema Area and Severity Index from baseline and an Investigator's Global Assessment score of 0 or 1 with a reduction of ≥2 points from baseline at week 16. The results showed that this trial reached the co-primary endpoints at week 16 with long-term treatment achieving sustained clinical benefits with a good safety profile. #mabs https://lnkd.in/ew5JfeZ7

Biocon Biologics just inked a 10-year supply deal with Eris Lifesciences worth Rs 1242 crore!🚀 📌This collaboration aims to expand patient access to critical healthcare products like Metabolics, Oncology, and Critical Care across India. 📌The deal, effective April 1, 2024, underscores Biocon Biologics' commitment to maximizing patient reach and market potential. 📌Over 430 employees will transition to Eris as part of this strategic move. 📌With this partnership, Biocon Biologics continues its mission to unlock value from its branded formulations legacy, aligning with its existing partnership with Eris for Nephrology and Dermatology products. 📌Notably, the acquisition brings two major insulin brands, Basalog and Insugen, under the Eris umbrella, boosting its Diabetes care franchise significantly. 📌This expansion will propel Eris's Diabetes care revenue to approximately Rs 1,000 crore, solidifying its position as the 5th largest diabetes portfolio in India. Source: https://lnkd.in/d5AehnXc #biocon #erislifesciences #bioconbiologics #linkedin #linkedingrowth #linkedlnpost #metabolics #oncology #diabetes

Benign Prostatic Hyperplasia Treatment Market Worth $14.1 Billion Request Free Sample Report: https://lnkd.in/d4G9Dx2M Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA], End User (Hospitals) - Global Forecast to 2026 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Boston Scientific, Coloplast, Teleflex, Olympus Corporation, GlaxoSmithKline Consumer Healthcare, L.P., Eli Lilly and Company, @Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US) Other Companies that are Operating in this Market Globally:   Kindeva Drug Delivery Smith Drug Company Pharmalink Drug Store Egyptian Drug Authority United Drug Aizant Drug Research Solutions Pvt Ltd Shoppers Drug Mart Specialty Health Network   PDA - Parenteral Drug Association    Metro Drug, Inc. The Cathay Drug Company Inc.     PT Metro Drug Indonesia Lewis Family Drug Catalent Pharma Solutions Grifols Novo Nordisk Cipla EMS Ranbaxy Himalaya Wellness Company Aspen Pharma Group PT Kalbe Farma, Tbk VINH PHUC PHARMACEUTICAL JOINT - STOCK COMPANY Servier Medpace #BPH #ProstateHealth #BPHTreatment #Urology #MenHealth

Uncovering Hidden Costs in nAMD Clinics In the quest for cost-effectiveness, are we missing a crucial piece of the puzzle? Our latest publication "Real-world service costs for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis" published in Current Medical Research and Opinion, reveals the significant strain costs impacting nAMD clinics, often overlooked in traditional cost-effectiveness analyses. In our scenario analysis, Drug A may appear cheaper with a lower upfront cost (£10), the associated strain costs (£13,115) paint a different picture compared to Drug B (£100 upfront with no additional strain costs). What does this mean? • Drug A: Lower initial cost but significant long-term strain costs. • Drug B: Higher initial cost but no additional strain costs. Impact on decision-making: When evaluating options, it's essential to consider not just the drug costs, but also the broader economic impact on the service as a whole. Incorporating strain costs into Health Technology Assessments (HTA) provides a more comprehensive view, ensuring sustainable and efficient healthcare delivery. Read the full article to explore our findings and methodology in detail: https://lnkd.in/d2-gjXba Get in touch with Medialis Ltd at info@medialis.co.uk to help shift your focus to more holistic evaluations that account for all costs, fostering better decision-making and improved patient care. Join the conversation and share your insights on how we can better integrate these findings into our practices. #nAMD #HealthcareEconomics #CostEffectiveness #HTA #HealthcareInnovation #nASInstrument #DiseaseSpecific Actelion (now Janssen Pulmonary Hypertension), Actinium Pharmaceuticals, Inc., Alkermes, Bazell Pharma, Bio-Path Holdings, Camurus, Corbus Pharmaceuticals, Delta-Fly Pharma株式会社, Elevation Oncology, Gossamer Bio, Geron Corporation, Goldfinch Bio, I-Mab Biopharma, Imara Inc., IMMUNOVACCINE TECHNOLOGIES, Kiniksa Pharmaceuticals, Marker Therapeutics, Inc., MedImmune, MorphoSys, Otsuka Pharmaceutical Development & Commercialization, Inc., PTC Therapeutics, Inc., Scholar Rock, SCYNEXIS, Inc., Sobi - Swedish Orphan Biovitrum AB (publ), Taiho Oncology, Inc., Teclison